Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?
Use of atypical antipsychotics (AAPs) for attention-deficit/hyperactivity disorder (ADHD) is currently rife and trend of use is on the rise. It is largely off-label driven. Here, we touch on the topic highlighting both merits and demerits of this approach.
Gespeichert in:
| Veröffentlicht in: | European psychiatry 2019-10, Vol.62, p.58-59 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59 |
|---|---|
| container_issue | |
| container_start_page | 58 |
| container_title | European psychiatry |
| container_volume | 62 |
| creator | Naguy, Ahmed Hashem, Mohamed S AlKhadhar, Sulaiman |
| description | Use of atypical antipsychotics (AAPs) for
attention-deficit/hyperactivity disorder (ADHD) is currently rife and trend
of use is on the rise. It is largely off-label driven. Here, we touch on the
topic highlighting both merits and demerits of this approach. |
| doi_str_mv | 10.1016/j.eurpsy.2019.08.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2296141376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924933819301476</els_id><sourcerecordid>2296141376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-a4d3a977439edd1442f862f8f9b7a684bb01e8f9ec12aec3b9d3cbe709d3f9c33</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EglL4BghlZGhSO3aTeAFV5U-RKrHAxGA59kW4SpNgO5Xy7XGVwshwOt3pvXu6H0I3BCcEk2y-TaC3nRuSFBOe4CLBhJ6gCcnzIqaLYnGKJpinLOaUFhfo0rktxiTHODtHF5QsWMo4nqDPpR86o2QdycabcE59td4oF1WtjZbeQ9i2TfwIlVHGz9dDB1Yqb_bGD5E2rrUabBw5ZaBRMIuk9bMoWCupH67QWSVrB9fHPkUfz0_vq3W8eXt5XS03sWK48LFkmkqe54xy0JowllZFFqriZS6zgpUlJhAmUCSVoGjJNVUl5Dj0iitKp-huvNvZ9rsH58XOOAV1LRtoeyfSlGeEEZpnQcpGqbKtcxYq0Vmzk3YQBIsDVrEVI1ZxwCpwIQLWYLs9JvTlDvSf6ZdjENyPAgh_7g1YcSSijQXlhW7N_wk_YM2Mog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2296141376</pqid></control><display><type>article</type><title>Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Naguy, Ahmed ; Hashem, Mohamed S ; AlKhadhar, Sulaiman</creator><creatorcontrib>Naguy, Ahmed ; Hashem, Mohamed S ; AlKhadhar, Sulaiman</creatorcontrib><description>Use of atypical antipsychotics (AAPs) for
attention-deficit/hyperactivity disorder (ADHD) is currently rife and trend
of use is on the rise. It is largely off-label driven. Here, we touch on the
topic highlighting both merits and demerits of this approach.</description><identifier>ISSN: 0924-9338</identifier><identifier>EISSN: 1778-3585</identifier><identifier>DOI: 10.1016/j.eurpsy.2019.08.013</identifier><identifier>PMID: 31542490</identifier><language>eng</language><publisher>England: Elsevier Masson SAS</publisher><subject>Adolescent ; Antipsychotic Agents ; Attention Deficit and Disruptive Behavior Disorders ; Attention Deficit Disorder with Hyperactivity ; Child ; Comorbidity ; Humans ; Risperidone</subject><ispartof>European psychiatry, 2019-10, Vol.62, p.58-59</ispartof><rights>2019 Elsevier Masson SAS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-a4d3a977439edd1442f862f8f9b7a684bb01e8f9ec12aec3b9d3cbe709d3f9c33</citedby><cites>FETCH-LOGICAL-c408t-a4d3a977439edd1442f862f8f9b7a684bb01e8f9ec12aec3b9d3cbe709d3f9c33</cites><orcidid>0000-0002-6465-456X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31542490$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naguy, Ahmed</creatorcontrib><creatorcontrib>Hashem, Mohamed S</creatorcontrib><creatorcontrib>AlKhadhar, Sulaiman</creatorcontrib><title>Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?</title><title>European psychiatry</title><addtitle>Eur Psychiatry</addtitle><description>Use of atypical antipsychotics (AAPs) for
attention-deficit/hyperactivity disorder (ADHD) is currently rife and trend
of use is on the rise. It is largely off-label driven. Here, we touch on the
topic highlighting both merits and demerits of this approach.</description><subject>Adolescent</subject><subject>Antipsychotic Agents</subject><subject>Attention Deficit and Disruptive Behavior Disorders</subject><subject>Attention Deficit Disorder with Hyperactivity</subject><subject>Child</subject><subject>Comorbidity</subject><subject>Humans</subject><subject>Risperidone</subject><issn>0924-9338</issn><issn>1778-3585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxS0EglL4BghlZGhSO3aTeAFV5U-RKrHAxGA59kW4SpNgO5Xy7XGVwshwOt3pvXu6H0I3BCcEk2y-TaC3nRuSFBOe4CLBhJ6gCcnzIqaLYnGKJpinLOaUFhfo0rktxiTHODtHF5QsWMo4nqDPpR86o2QdycabcE59td4oF1WtjZbeQ9i2TfwIlVHGz9dDB1Yqb_bGD5E2rrUabBw5ZaBRMIuk9bMoWCupH67QWSVrB9fHPkUfz0_vq3W8eXt5XS03sWK48LFkmkqe54xy0JowllZFFqriZS6zgpUlJhAmUCSVoGjJNVUl5Dj0iitKp-huvNvZ9rsH58XOOAV1LRtoeyfSlGeEEZpnQcpGqbKtcxYq0Vmzk3YQBIsDVrEVI1ZxwCpwIQLWYLs9JvTlDvSf6ZdjENyPAgh_7g1YcSSijQXlhW7N_wk_YM2Mog</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Naguy, Ahmed</creator><creator>Hashem, Mohamed S</creator><creator>AlKhadhar, Sulaiman</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6465-456X</orcidid></search><sort><creationdate>201910</creationdate><title>Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?</title><author>Naguy, Ahmed ; Hashem, Mohamed S ; AlKhadhar, Sulaiman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-a4d3a977439edd1442f862f8f9b7a684bb01e8f9ec12aec3b9d3cbe709d3f9c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Antipsychotic Agents</topic><topic>Attention Deficit and Disruptive Behavior Disorders</topic><topic>Attention Deficit Disorder with Hyperactivity</topic><topic>Child</topic><topic>Comorbidity</topic><topic>Humans</topic><topic>Risperidone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naguy, Ahmed</creatorcontrib><creatorcontrib>Hashem, Mohamed S</creatorcontrib><creatorcontrib>AlKhadhar, Sulaiman</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naguy, Ahmed</au><au>Hashem, Mohamed S</au><au>AlKhadhar, Sulaiman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?</atitle><jtitle>European psychiatry</jtitle><addtitle>Eur Psychiatry</addtitle><date>2019-10</date><risdate>2019</risdate><volume>62</volume><spage>58</spage><epage>59</epage><pages>58-59</pages><issn>0924-9338</issn><eissn>1778-3585</eissn><abstract>Use of atypical antipsychotics (AAPs) for
attention-deficit/hyperactivity disorder (ADHD) is currently rife and trend
of use is on the rise. It is largely off-label driven. Here, we touch on the
topic highlighting both merits and demerits of this approach.</abstract><cop>England</cop><pub>Elsevier Masson SAS</pub><pmid>31542490</pmid><doi>10.1016/j.eurpsy.2019.08.013</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-6465-456X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-9338 |
| ispartof | European psychiatry, 2019-10, Vol.62, p.58-59 |
| issn | 0924-9338 1778-3585 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2296141376 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Antipsychotic Agents Attention Deficit and Disruptive Behavior Disorders Attention Deficit Disorder with Hyperactivity Child Comorbidity Humans Risperidone |
| title | Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T07%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atypical%20antipsychotics%20for%20Attention-Deficit/Hyperactivity%20disorder-%20science,%20art,%20or%20fad?&rft.jtitle=European%20psychiatry&rft.au=Naguy,%20Ahmed&rft.date=2019-10&rft.volume=62&rft.spage=58&rft.epage=59&rft.pages=58-59&rft.issn=0924-9338&rft.eissn=1778-3585&rft_id=info:doi/10.1016/j.eurpsy.2019.08.013&rft_dat=%3Cproquest_cross%3E2296141376%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2296141376&rft_id=info:pmid/31542490&rft_els_id=S0924933819301476&rfr_iscdi=true |